References
- Baker M, Parton T. (2007). Kinetic determinants of hepatic clearance: plasma protein binding and hepatic uptake. Xenobiotica 37:1110–34
- Berezhkovskiy LM. (2004). Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J Pharm Sci 93:364–74
- Chmurzynska A. (2006). The multi-gene family of fatty acid binding proteins (FABPs): function, structure and polymorphism. J Appl Genet 47:39–48
- Chuang S, Velkov T, Horne J, et al. (2008). Characterization of the drug binding specificity of rat liver fatty acid binding protein. J Med Chem 51:3755–64
- Fehske KJ, Schläfer U, Wollert U, Müller WE. (1982). Characterization of an important drug binding area on human serum albumin including the high-affinity binding sites of warfarin and azapropazone. Mol Pharmacol 21:387–93
- Frostell-Karlsson A, Remaeus A, Roos H, et al. (2000). Biosensor analysis of the interaction between immobilised human serum albumin and drug compounds for prediction of human serum albumin binding levels. J Med Chem 43:1986–92
- Furuhashi M, Hotamisligil GS. (2008). Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 7:489–503
- Hage DS, Noctor TA, Wainer IW. (1995). Characterization of the protein binding of chiral drugs by high-performance affinity chromatography. Interactions of R-and S-ibuprofen with human serum albumin. J Chromatogr A 693:23–32
- Hamilton JA. (2004). Fatty acid interactions with proteins: what X-ray crystal and NMR solution structures tell us. Prog Lipid Res 43:177–99
- Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the folin phenol reagent. J Biol Chem 193:265–75
- Maatman RGHJ, van Moerkerk HT, Nooren IM, et al. (1994). Expression of human liver fatty acid binding protein in Escherichia coli and comparative analysis of its binding characteristics with muscle fatty acid binding protein. Biochim Biophys Acta 1214:1–10
- Norris AW, Spector AA. (2002). Very long chain n-3 and n-6 polyunsaturated fatty acids binding strongly to liver fatty acid-binding protein. J Lipid Res 43:646–53
- Rich RL, Day YSN, Morton TA, Myszka DG. (2001). High resolution and high-throughput protocols for measuring drug/human serum albumin interactions using BIACORE. Anal Biochem 296:197–207
- Rowland A, Knights KM, Mackenzie PI, Miners JO. (2009). Characterization of the binding of drugs to human intestinal fatty acid binding protein (IFABP): potential role of IFABP as an alternative to albumin for in vitro-in vivo extrapolation of drug kinetic parameters. Drug Metab Dispos 37:1395–403
- Takikawa H, Kaplowitz N. (1986). Binding of bile acids, oleic acid and organic anions by rat and human hepatic Z protein. Arch Biochem Biophys 251:385–92
- Thompson J, Winter N, Terwey D, et al. (1997). The crystal structure of liver fatty acid binding protein; a complex with two bound oleates. J Biol Chem 272:7140–50
- Thompson J, Ory J, Reese-Wagoner A, Banaszak L. (1999). The liver fatty acid binding protein-comparison of cavity properties of intracellular lipid-binding proteins. Mol Cell Biochem 192:9–16
- Veerkamp JH, Maatman RG. (1995). Cytoplasmic fatty acid binding proteins: their structure and genes. Prog Lipid Res 34:17–52
- Veerkamp JH, van Moerkerk HTB, Prinsen CFM, van Kappevelt TH. (1999). Structural and functional studies on different FABP types. Mol Cell Biochem 192:137–42
- Wright JD, Boudinot FD, Ujhelyi MR. (1996). Measurement and analysis of unbound drug concentrations. Clin Pharmacokinet 30:445–62
- Yamasaki K, Chuang VT, Maruyama T, Otagiri M. (2013). Albumin-drug interaction and its clinical implication. Biochim Biophys Acta 1830:5435–43
- Zimmerman AW, Veerkamp JH. (2002). New insights into the structure and function of fatty acid-binding proteins. Cell Mol Life Sci 59:1096–116